Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine R Tuttle

Showing results (81-90 of 355) with videos related to

Pageof 36
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 27, 2020
We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney InjuryVikas S Sridhar, Katherine R Tuttle, David Z I Cherney
Seminars in Nephrology|May 5, 2024
Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney DiseaseChristine P Limonte, Julio A Lamprea-Montealegre, Katherine R Tuttle
Kidney & Blood Pressure Research|July 11, 2012
Classification of chronic kidney disease biomarkers to predict coronary artery calciumSterling McPherson, Celestina Barbosa-Leiker, Robert Short, et al.
Kidney International|April 16, 2024
The authors replyWinston W S Fung, Valerie A Luyckx, Katherine R Tuttle, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Reframing Chronicity with Urgency in Chronic Kidney Disease ManagementBrendon L Neuen, Katherine R Tuttle, George Bakris, et al.
American Journal of Physiology. Renal Physiology|August 26, 2016
Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targetsRaimund Pichler, Maryam Afkarian, Brad P Dieter, et al.
Journal of Nephrology|July 12, 2022
On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney diseaseCem Tanriover, Duygu Ucku, Carlo Basile, et al.
European Journal of Internal Medicine|May 14, 2023
Tirzepatide and potential use for metabolically healthy obesitySidar Copur, Cem Tanriover, Furkan Yavuz, et al.
Lancet (London, England)|January 17, 2026
Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefitsMichael A Nauck, Katherine R Tuttle, Matthias H Tschöp, et al.
Nature Clinical Practice. Nephrology|August 26, 2006
Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndromeTakahiko Nakagawa, Katherine R Tuttle, Robert A Short, et al.
Pageof 36

Showing results (81-90 of 355) with videos related to

Sort By:
Pageof 36
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 27, 2020
We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney InjuryVikas S Sridhar, Katherine R Tuttle, David Z I Cherney
Seminars in Nephrology|May 5, 2024
Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney DiseaseChristine P Limonte, Julio A Lamprea-Montealegre, Katherine R Tuttle
Kidney & Blood Pressure Research|July 11, 2012
Classification of chronic kidney disease biomarkers to predict coronary artery calciumSterling McPherson, Celestina Barbosa-Leiker, Robert Short, et al.
Kidney International|April 16, 2024
The authors replyWinston W S Fung, Valerie A Luyckx, Katherine R Tuttle, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Reframing Chronicity with Urgency in Chronic Kidney Disease ManagementBrendon L Neuen, Katherine R Tuttle, George Bakris, et al.
American Journal of Physiology. Renal Physiology|August 26, 2016
Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targetsRaimund Pichler, Maryam Afkarian, Brad P Dieter, et al.
Journal of Nephrology|July 12, 2022
On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney diseaseCem Tanriover, Duygu Ucku, Carlo Basile, et al.
European Journal of Internal Medicine|May 14, 2023
Tirzepatide and potential use for metabolically healthy obesitySidar Copur, Cem Tanriover, Furkan Yavuz, et al.
Lancet (London, England)|January 17, 2026
Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefitsMichael A Nauck, Katherine R Tuttle, Matthias H Tschöp, et al.
Nature Clinical Practice. Nephrology|August 26, 2006
Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndromeTakahiko Nakagawa, Katherine R Tuttle, Robert A Short, et al.
Pageof 36